Key Highlights

  • H1 2026 adjusted Operating Margin rose to 23.0% (+140bps); adjusted diluted EPS up ~29% to 8.5 cents.
  • Revenue of $318.2m grew 4.7% organically; adjusted operating profit up 9.8% to $73.2m.
  • Pure-play pivot complete: talc, chromium and pharma Manufacturing divested; Alchemy acquired for personal care.
  • Net Debt fell to $163.8m (1.1x); Interim Dividend up ~15% to 1.5c and a £25m buyback underway.
  • FY26 guidance reaffirmed: adjusted EBITA ~$135m, margins above 23%, ROCE above 30%, net debt near 1.0x.

Elementis (LSE:ELM) has spent several years reshaping itself from a diversified, part-commodity chemicals group into a focused specialty-additives business, and its first-half 2026 results suggest the strategy is now bearing fruit. The company reported Revenue of $318.2 million, up 4.7% on an organic constant-currency basis, and lifted its adjusted operating margin to 23.0% - a 140 basis-point expansion - with adjusted Diluted Earnings per Share rising almost 29% to 8.5 cents. Management described the outcome as ahead of expectations, and the shares reacted positively.

The result crystallises the Investment thesis that has been building around Elementis: a higher-quality, higher-margin Business with genuine pricing power in niche additive markets. With Commodity operations now divested, the group is a cleaner play on personal care and coatings demand, and the first half showed both divisions contributing to the margin story.

Latest Development

The half-year results, covering the six months to 30 June 2026, were the key catalyst. Beyond the headline profitability improvement, the standout strategic message was the completion of Elementis' pivot to a 'pure-play specialty chemicals' company. Over recent periods the group has exited commodity-style activities - including talc, chromium and pharmaceutical manufacturing - while adding capability in personal care through the Alchemy acquisition, sharpening the portfolio around its highest-return franchises.

Capital returns also stepped up. The board raised the interim dividend by around 15% to 1.5 cents per share and progressed a share buyback, with net repurchases in the period sitting within a £25 million programme launched in June 2026. Net debt fell to $163.8 million from $185.4 million at the end of 2025, leaving Leverage at a comfortable 1.1x EBITDA - a Balance Sheet that now supports returns rather than constrains them.

The Numbers

Group adjusted operating profit rose 9.8% to $73.2 million, driving the margin to 23.0% from 21.6%. Within the divisions, Coatings was the stronger performer: revenue grew 5.6% organically to $209.0 million and its operating margin expanded 250 basis points to 20.7%, with adjusted operating profit of $43.2 million. Personal Care delivered $109.2 million of revenue, up 2.9% organically, at a rich 38.1% operating margin (up 30 basis points) and $41.6 million of profit - a reminder that this is the group's crown-jewel franchise.

The balance sheet strengthened materially, with net debt down to $163.8 million and leverage at 1.1x. For the full year, management reaffirmed confidence in meeting expectations, guiding to adjusted EBITA broadly in line with the market's roughly $135 million view, mid-single-digit organic revenue growth, margins above 23%, return on Capital employed above 30% and net debt near 1.0x EBITDA - a coherent framework for a business now optimised around quality and cash generation.

The Investment Story

Elementis operates in two attractive additive markets. In Personal Care it supplies rheology modifiers, actives and hectorite-based ingredients to cosmetics and skincare formulators, benefiting from control of high-purity hectorite clay reserves at Newberry Springs, California - a genuine raw-material moat. In Coatings it provides additives that control the flow, texture and performance of paints and industrial coatings. Both are small-dollar, high-value inputs that command strong margins and sticky customer relationships, insulating the group somewhat from raw-material volatility.

The strategic logic of the pure-play pivot is to concentrate capital on these franchises, lift group margins and returns, and use a de-levered balance sheet to fund bolt-on growth such as Alchemy and to return cash to shareholders. Competitive strengths include formulation expertise, technical service and the hectorite reserve base; the growth strategy blends organic innovation in personal care with operational efficiency in coatings.

What Could Drive the Shares?

Continued margin expansion is the most direct driver. If Coatings keeps closing the gap towards Personal Care's profitability and the group holds margins above 23%, the market may reward Elementis with a specialty-chemicals rating closer to higher-quality peers. Delivery on the buyback and progressive dividend, funded by a strong balance sheet, adds a capital-returns angle.

Volume recovery in coatings end-markets, successful integration and cross-selling of Alchemy in personal care, and further bolt-on M&A funded from the de-levered balance sheet could all reinforce the growth narrative. Meeting or beating the roughly $135 million full-year EBITA expectation would validate the transformation and could support sentiment.

Risks Investors Should Watch

As a specialty supplier, Elementis remains exposed to end-market Demand cycles in cosmetics, construction and industrial coatings, and to destocking or weakness among its customers. Management flagged Middle East geopolitical risk as a potential drag on demand and Supply chains. Raw-material and energy cost inflation, foreign-exchange translation (the group reports in dollars while London-listed), and integration risk on acquisitions are further considerations.

What Happens Next?

The near-term calendar points to a Q3 trading update and then full-year 2026 results in early 2027, which will test delivery against the reaffirmed guidance - adjusted EBITA around $135 million, margins above 23% and ROCE above 30%. Investors will watch the pace of the £25 million buyback, progress on Alchemy integration, and any further capital-allocation signals now that leverage sits near 1.0x. Commentary on coatings volumes and personal-care momentum into the second half will shape the outlook.

Bottom Line

Elementis (LSE:ELM)' first half showed a leaner, higher-margin business delivering ahead of expectations, with the pure-play specialty-chemicals transformation now essentially complete and the balance sheet strong enough to fund both growth and returns. The bull case is a durable re-rating as margins, returns and cash generation prove sustainable. The risk case is that specialty-additive demand softens or geopolitical and cost pressures interrupt the momentum. On the evidence of the first half, the margin story is real - the question the headline poses is whether it can keep running, and that now rests on end-market demand rather than self-help.

What to Watch

  • Whether Coatings margins keep converging towards Personal Care's ~38%.
  • Pace and completion of the £25m share buyback and dividend progression.
  • Alchemy integration and any further bolt-on M&A.
  • Coatings and personal-care Volume trends into H2 2026.
  • Full-year 2026 results in early 2027 versus the ~$135m EBITA and >23% margin targets.